

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 8, 2024

Enliven Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction
of incorporation)

001-39247

(Commission
File Number)

81-1523849

(IRS Employer
Identification No.)

6200 Lookout Road
Boulder, Colorado

(Address of principal executive offices)

80301

(Zip Code)

Registrant's telephone number, including area code: 720 647-8519

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.001 per share	ELVN	The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

(d) Election of Directors

On April 8, 2024, the Board of Directors (the “Board”) of Enliven Therapeutics, Inc. (the “Company”) appointed Lori Kunkel, MD to serve as a Class III director, with a term expiring at the Company’s 2026 annual meeting of stockholders.

There are no arrangements or understandings between Dr. Kunkel and any other person pursuant to which Dr. Kunkel was selected as a director. In addition, there are no transactions in which Dr. Kunkel has an interest that would require disclosure under Item 404(a) of Regulation S-K.

Dr. Kunkel will receive compensation for her service pursuant to the Company’s outside director compensation policy. This includes an annual cash retainer of \$35,000 per year for service as an outside director. Additionally, as a new outside director, Dr. Kunkel was granted stock options to purchase shares with a grant date fair value as determined in accordance with U.S. generally accepted accounting principles equal to approximately \$500,000. These stock options vest as to 1/36th of the total number of shares on each monthly anniversary of the grant date, subject to Dr. Kunkel’s continued service through the applicable vesting date. In the event of a Change in Control (as defined in the Company’s Outside Director Compensation Policy), the stock options will vest in full. In addition, Dr. Kunkel also executed the Company’s standard form of indemnification agreement.

A copy of the press release announcing Dr. Kunkel’s appointment as a director is attached hereto as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

<u>Exhibit Number</u>	<u>Exhibit Description</u>
99.1	Press release dated April 9, 2024
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Enliven Therapeutics, Inc.

Date: April 9, 2024

By: /s/ Samuel Kintz
Name: Samuel Kintz
Title: President and Chief Executive Officer



Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors

BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) – Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced the appointment of Lori Kunkel, MD, to its Board of Directors. Dr. Kunkel brings more than twenty-five years of experience in oncology and immunology drug development and commercialization to the Board.

“Lori has served as scientific advisor to Enliven since its inception, and we are delighted to now welcome her to our Board,” said Sam Kintz, MBA, Enliven’s Co-founder and Chief Executive Officer. “She brings a wealth of experience as a clinician, academic and industry executive, and we look forward to her continued contributions and insights as we advance our two parallel lead product candidates, ELVN-001 and ELVN-002, through the next set of clinical milestones.”

Dr. Kunkel is an accomplished industry executive and board member with a track record of success in corporate strategy, clinical development and commercialization, and business development. She currently serves on the Board of Directors of Nurix Therapeutics, Inc., ORIC Pharmaceuticals, Inc., and K36 Therapeutics, Inc. She is also a scientific advisor to several clinical-stage oncology and immunotherapy companies. Previously, Dr. Kunkel was the acting Chief Medical Officer (CMO) and board member of Loxo Oncology, Inc. (acquired by Eli Lilly and Company). She also served as the CMO at Pharmacyclics LLC (acquired by AbbVie) and Proteolix, Inc. (acquired by Onyx Pharmaceuticals).

Prior to joining industry, Dr. Kunkel spent ten years in academic medicine and served as a faculty member at the Bone Marrow Transplant Unit in the Division of Hematology/Oncology at the University of California, Los Angeles. She received her medical degree from University of Southern California and her bachelor’s degree in biology from University of California, San Diego. She is board certified in internal medicine and held board certifications in hematology and oncology.

“I am honored to transition from my role as a scientific advisor to a member of the Board of Directors,” said Dr. Kunkel. “I have been deeply engaged with the science at Enliven since the beginning, and I am thrilled to now play a more direct role in guiding its strategic direction. With the Company’s upcoming announcement of initial proof-of-concept data from the ongoing Phase 1a trial of ELVN-001, it is an exciting time for the Company.”

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help people with cancer not only live longer, but live better. Enliven aims to address existing and emerging unmet needs with a precision oncology approach that improves survival and enhances overall well-being. Enliven’s discovery process combines deep insights in clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. Enliven is based in Boulder, Colorado.

Contact:

Investors

ir@enliventherapeutics.com

Media

media@enliventherapeutics.com